Lyrica Generics Were Likely Delayed By A Pfizer Labeling Supplement
US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.
You may also be interested in...
A GDUFA III adjustment could allow more labeling changes during the review cycle and reduce assessment cycles.
The first generic versions of Pfizer's blockbuster pain medicine pregabalin have launched in the US. Pfizer has guided investors the company will return to growth in 2020 after cycling through the loss.
Several generic rivals to Pfizer’s Lyrica have hit the US market following the anti-seizure and pain brand’s loss of exclusivity.